Evidence map›Paper›PMID 36769029›Full record

ReviewInternational journal of molecular sciences2023

Health Benefits of Coffee Consumption for Cancer and Other Diseases and Mechanisms of Action.

Stephen Safe, Jainish Kothari, Amanuel Hailemariam, Srijana Upadhyay, Laurie A Davidson, Robert S Chapkin

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Towards Cytotoxic Derivatives of Cafestol.Molecules (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Coffee as a Source of Antioxidants and an Elixir of Youth.Antioxidants (Basel, Switzerland) · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen SafeDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-2115-3060
Jainish KothariMaster of Biotechnology Program, Texas A&M University, College Station, TX 77843, USA.
Amanuel HailemariamDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Srijana UpadhyayDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Laurie A DavidsonProgram in Integrative Nutrition and Complex Diseases, Department of Nutrition, Texas A&M University, College Station, TX 77843, USA.
Robert S ChapkinProgram in Integrative Nutrition and Complex Diseases, Department of Nutrition, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-6515-3898

Funding

Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Natalie M Johnson · 2019 to 2026
$13.0M
Plasma membrane therapy: Disruption of Wnt associated receptor spatiotemporal organization by membrane targeted dietary bioactives (MTDB)R35CA197707 · NCI · TEXAS A&M AGRILIFE RESEARCH · PI CHAPKIN, ROBERT STEPHEN · 2016 to 2022
$6.3M
Diet induced modifications of microbiota metabolites in colon tumorigenesisR01CA202697 · NCI · TEXAS A&M AGRILIFE RESEARCH · PI ALLRED, CLINTON D, CHAPKIN, ROBERT STEPHEN · 2016 to 2020
$2.0M
Role of Aryl Hydrocarbon Receptor in Microbiota-Colon Stem Cell InteractionsR01ES025713 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI CHAPKIN, ROBERT STEPHEN, JAYARAMAN, ARUL · 2016 to 2020
$2.0M
Nutrition, Biostatistics & Bioinformatics Training GrantT32CA090301 · NCI · TEXAS A&M UNIVERSITY · PI CARROLL, RAYMOND J. · 2016 to 2020
$712k
Cancer Prevention Research Institute of Texas RP160589NCI NIH HHS R01 CA202697NCI NIH HHS R35 CA197707NCI NIH HHS T32 CA090301NIEHS NIH HHS P30 ES029067NIEHS NIH HHS R01 ES025713NIH HHS P30-ES029067NIH HHS R01-CA202697NIH HHS R01-ES025713NIH HHS R35-CA197707NIH HHS T32-CA090301
6 · The paper itself

Abstract

Coffee is one of the most widely consumed beverages worldwide, and epidemiology studies associate higher coffee consumption with decreased rates of mortality and decreased rates of neurological and metabolic diseases, including Parkinson's disease and type 2 diabetes. In addition, there is also evidence that higher coffee consumption is associated with lower rates of colon and rectal cancer, as well as breast, endometrial, and other cancers, although for some of these cancers, the results are conflicting. These studies reflect the chemopreventive effects of coffee; there is also evidence that coffee consumption may be therapeutic for some forms of breast and colon cancer, and this needs to be further investigated. The mechanisms associated with the chemopreventive or chemotherapeutic effects of over 1000 individual compounds in roasted coffee are complex and may vary with different diseases. Some of these mechanisms may be related to nuclear factor erythroid 2 (Nrf2)-regulated pathways that target oxidative stress or pathways that induce reactive oxygen species to kill diseased cells (primarily therapeutic). There is evidence for the involvement of receptors which include the aryl hydrocarbon receptor (AhR) and orphan nuclear receptor 4A1 (NR4A1), as well as contributions from epigenetic pathways and the gut microbiome. Further elucidation of the mechanisms will facilitate the potential future clinical applications of coffee extracts for treating cancer and other inflammatory diseases.

Indexed as

Anticarcinogenic AgentsDiabetes Mellitus, Type 2NeoplasmsCoffeeHumansOxidative StressReactive Oxygen SpeciesAnticarcinogenic AgentsCoffeeReactive Oxygen SpeciesAH receptorcoffeehealthNrf2redox

Identifiers

PMID36769029
PMCPMC9916720

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.